II. History
- Sir James Black and Propranolol
- Sir James Black won 1988 Nobel Prize for Propranolol
- Synthesized Propranolol first in the 1960's
- Revolutionized cardiovascular medicine
III. Indications
-
Hypertension
- Not first line for Hypertension unless other comorbid cardiovascular indications (e.g. Coronary Artery Disease, chronic stable CHF)
- Atrial Fibrillation Rate Control
- Coronary Artery Disease without prior Myocardial Infarction
-
Myocardial Infarction (esp. with reduced ejection fraction <50%)
- Continue for at least 1 year after Myocardial Infarction (previously recommended for 3 years)
- Primary benefit in Post-MI is for those with reduced ejection fraction (<50%)
- Post-MI with revascularization and preserved ejection fraction appears to benefit little from Beta Blockers
- Yndigegn (2024) N Engl J Med 390(15):1372-81 +PMID: 38587241 [PubMed]
- Stable Congestive Heart Failure (Carvedilol, Metoprolol, Bisoprolol)
- Continue Beta Blocker indefinately
-
Arrhythmia refractory to other modality
- Recurrent Ventricular Tachycardia
- Recurrent Ventricular Fibrillation
- Migraine Prophylaxis
- Endocrinopathy
- Thyroid Storm
- Pheochromocytoma
- Never use Beta Blocker without Alpha Adrenergic ReceptorAntagonist in Pheochromocytoma
- Open Angle Glaucoma
IV. Contraindications
- Reactive Airway Disease and Obstructive Lung Disease (Asthma, COPD)
- Cardioselective Beta Blockers (e.g. Metoprolol) are not contraindicated in COPD
- Do not reduce effectiveness of beta Agonists (Bronchodilators)
- Recommended for decreased mortality, decreased Tachycardia with beta Agonists
- Avoid non-selective Beta Blockers (Carvedilol, Propranolol)
- See Bronchospasm under adverse effects below
- Cardioselective Beta Blockers (e.g. Metoprolol) are not contraindicated in COPD
- Acute Congestive Heart Failure exascerbation (decompensated CHF)
- Concurrent Non-Dihydropyridine Calcium Channel Blocker (e.g. Diltiazem, Verapamil) use
- Relative contraindication (risk of AV Block, Bradycardia)
V. Precautions
- Abrupt discontinuation is associated with exacerbation of Angina and risk of MI (FDA black box warning)
- Taper over one to two weeks
VI. Mechanism: General
- Beta Adrenergic Receptor Antagonist
- Inhibits effects of circulating Catecholamines
- Blocks Beta Adrenergic Receptors
- Beta-1 Adrenergic Receptors (Selective Beta Blockers primarily inhibit B1)
- Beta-2 Adrenergic Receptors
- Smooth Muscle and Bronchioles
- Beta-3 Adrenergic Receptors
- Lipolysis
VII. Mechanism: Cardiovascular Specific (Beta-1 Adrenergic Receptor blockade)
-
General Cardiac Effects
- Negative Inotrope
- Reduces Myocardial Contractility
- Negative Chronotrope
- Reduces Heart Rate
- Reduces Blood Pressure
- Reduces Myocardial Oxygen Demand
- Negative Inotrope
-
Antiarrhythmic effects
- Controls Catecholamine stimulated Arrhythmias
- Recurrent Ventricular Tachycardia
- Recurrent Ventricular Fibrillation
- Controls Myocardial Ischemia related Arrhythmias
- Reduces AV Nodal Conduction
- Slows ventricular response
- Quinidine-like effect on Action Potential
- Seen with Propranolol
- Controls Catecholamine stimulated Arrhythmias
- Myocardial protection
- Reduces Myocardial Infarction size
- Prevents re-infarction after Thrombolytic
VIII. Mechanism: Non-Selective effects (non-cardiovascular effects)
-
Beta 2 Adrenergic Receptor blockade
- Results in bronchoconstriction
- Beta 2 Adrenergic Receptors affect Bronchiole and Smooth Muscles
- Non-Selective Beta Blockers (e.g. Propranolol)
- Selective Beta Blockers lose selectivity at high dose and in Overdose
- High dose Metoprolol (over 200 mg/day)
- High dose Esmolol (over 300 ug/kg/min)
- Results in bronchoconstriction
- Beta 3 Adrenergic Receptor blockade
- Lipolysis inhibited
IX. Adverse Effects
- SA and AV nodal blockade
- Avoid in over age 75 unless secondary indication
- Do not use with Calcium Channel Blockers
- Hypotension or Orthostasis
-
Congestive Heart Failure
- Treat with vasodilators and Diuretics with inotropes
-
Bradycardia
- Treat with Atropine, Transcutaneous Pacing, Dopamine
- Bronchospasm
- Treat with Sympathomimetics and Aminophylline
- Unlikely to occur in cardioselective Beta Blockers at standard doses
- Study looked at Atenolol, Metoprolol, Bisoprolol
- First dose may lower FEV1 (responds to Albuterol)
- Continuous use does not impair lung function
- Salpeter (2002) Ann Intern Med 137:715-25 [PubMed]
- Major Depression exacerbation
- Fatigue
X. Drug Interactions
- Decreased Heart Rate and AV Conduction (cummulative effects of multiple agents acting at AV Node)
- Beta Blockers potentiate effects of other agents
XI. Preparations: Cardioselective (Beta-1 Selective Adrenergic Blockade)
-
Atenolol (Tenormin)
- Despite daily dosing, duration of activity is not a a full 24 hours
- Consider dividing dosing into twice daily (e.g. 50 mg twice daily)
- Not as effective as other Beta Blockers in cardiovascular disease prevention (especially with Hypertension present)
- Consider Metoprolol, Bisoprolol, Carvedilol or Nadolol instead
- Carlberg (2004) Lancet 364:1684-9 [PubMed]
- Dosing Adults
- Start: 25-50 mg orally daily
- Target: 50-100 mg orally daily (may divide dose twice daily)
- Maximum dose: 100 mg (50 mg if GFR <35 ml/min, 25 mg if GFR <15 ml/min)
- Despite daily dosing, duration of activity is not a a full 24 hours
-
Metoprolol (Lopressor, Toprol XL)
- See Metoprolol
- Preferred Beta Blocker for Hypertension, Myocardial Infarction, Atrial Fibrillation Rate Control
- Metoprolol Succinate (Toprol XL) is preferred over Metoprolol Tartrate (Lopressor)
-
Bisoprolol (Zebeta)
- Most cardioselective of Beta Blockers
- Start: 2.5 to 5 mg orally daily
- Maximum: 20 mg/day
-
Betaxolol (Kerlone)
- Start: 5 mg orally daily
- Maximum: 20 mg/day
-
Acebutolol (Sectral)
- Intrinsic Sympathomimetic activity (partial beta Agonist)
- Start: 400 mg orally daily or divided 200 mg orally twice daily
- Better efficacy when divided twice daily
- Target: 400 to 800 mg/day
- Maximum: 1200 mg/day
XII. Preparations: Nonselective (Beta-1 and Beta-2 Adrenergic Blockade)
-
Timolol (Blocadren)
- Dose: 10 mg orally twice daily (maximum 60 mg/day)
-
Nadolol (Corgard)
- Dose: 40 mg orally daily (maximum 320 mg/day)
- Decrease dose with Renal Insufficiency
-
Propranolol (Inderal)
- Used for Essential Tremor, symptomatic Hyperthyroidism, Migraine Prophylaxis, symptomatic Palpitations
-
Timolol
- See Intraocular Beta Blocker
- Typically used topically for Open Angle Glaucoma
- Longer half life than Propranolol
-
Sotalol
- Primarily used as Antiarrhythmic
- Penbutalol (Levatol)
- Start: 20 mg orally daily
- Target: 20-40 mg orally daily
- Maximum: 80 mg/day
- Oxprenolol
- Dose: 80-160 mg orally divided twice to three times daily
- Maximum: 320 mg/day
- Carteolol (Cartrol)
- Start: 2.5 mg orally daily
- Target: 2.5 to 5 mg orally daily
- Maximum: 10 mg/day
- GFR <60: decrease dose to every 48 hours
-
Pindolol (Visken)
- Intrinsic Sympathomimetic activity (partial beta Agonist), similar to Acebutolol
- Start: 5 mg orally twice daily
- Target: 5 to 15 mg orally twice daily
- Maximum: 60 mg/day
XIII. Preparations: Combined Beta Blocker and Vasodilator
- Combined Alpha-1, Beta-1 and Beta-2 Adrenergic Blockade
- Labetalol
- Carvedilol (Coreg)
- Third generation Beta Blocker with vasodilatory properties (alpha blocker)
- Used in Congestive Heart Failure
- Combined Beta-1 and NItric Oxide (Beta-3 Agonist)
- Nebivolol (Bystolic)
- Third generation Beta Blocker with vasodilatory properties (nitric oxide release)
- Dosing
- Start: 5 mg orally (2.5 mg in hepatic Impairment or GFR <30 ml/min)
- Maximum: 40 mg/day
- Nebivolol (Bystolic)
XIV. Preparations: Parenteral Beta Blockers
- Metoprolol
- Labetalol
-
Esmolol Hydrochloride (Brevibloc)
- See Esmolol
- Intravenous very short acting, Beta-1 Selective Beta Blocker
- See Emergent Hypertension Management (esp. Aortic Dissection)
XV. References
- (2012) Presc Lett 19(12): 67-8
- Yen (2015) Crit Dec Emerg Med 29(10): 18-23
Images: Related links to external sites (from Bing)
Related Studies
carteolol (on 9/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
CARTEOLOL HCL 1% EYE DROPS | Generic | $1.19 per ml |
Ontology: Adrenergic beta-Antagonists (C0001645)
Definition (CHV) | a type of drug used for hypertension, migraine, cardiac infarction, etc |
Definition (CHV) | a type of drug used for hypertension, migraine, cardiac infarction, etc |
Definition (CHV) | a type of drug used for hypertension, migraine, cardiac infarction, etc |
Definition (CHV) | a type of drug used for hypertension, migraine, cardiac infarction, etc |
Definition (CHV) | a type of drug used for hypertension, migraine, cardiac infarction, etc |
Definition (CHV) | a type of drug used for hypertension, migraine, cardiac infarction, etc |
Definition (CHV) | a type of drug used for hypertension, migraine, cardiac infarction, etc |
Definition (CHV) | a type of drug used for hypertension, migraine, cardiac infarction, etc |
Definition (CHV) | a type of drug used for hypertension, migraine, cardiac infarction, etc |
Definition (CHV) | a type of drug used for hypertension, migraine, cardiac infarction, etc |
Definition (CHV) | a type of drug used for hypertension, migraine, cardiac infarction, etc |
Definition (NCI) | Natural or synthetic beta adrenergic antagonists selectively or non-selectively blocking or diminishing physiologic beta-adrenergic agonist actions on the sympathetic system. This group of antagonists are generally used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. |
Definition (NCI_CDISC) | Natural or synthetic beta adrenergic antagonists selectively or non-selectively blocking or diminishing physiologic beta-adrenergic agonist actions on the sympathetic system. This group of antagonists are generally used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. |
Definition (MSH) | Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. |
Concepts | Pharmacologic Substance (T121) |
MSH | D000319 |
SnomedCT | 318350007, 33252009, 373254001 |
LNC | LP18062-7, MTHU003324 |
English | beta Adrenergic Blocking Agents, beta Adrenergic Receptor Blockaders, beta Blockers, Adrenergic, Adrenergic beta Antagonists, Adrenergic beta Receptor Blockaders, Adrenergic beta-Blockers, Adrenergic beta-Receptor Blockaders, Agents, beta-Adrenergic Blocking, Blockaders, Adrenergic beta-Receptor, Blockaders, beta-Adrenergic Receptor, Blockers, beta-Adrenergic, Blocking Agents, beta-Adrenergic, Receptor Blockaders, beta-Adrenergic, beta Adrenergic Blockers, beta-Adrenergic Blockers, beta-Adrenergic Blocking Agents, beta-Adrenergic Receptor Blockaders, beta-Antagonists, Adrenergic, beta-Blockers, Adrenergic, beta-Receptor Blockaders, Adrenergic, Beta-adrenoceptor blocker, BETA BLOCKERS ADREN, ADREN BETA RECEPT BLOCK, BETA ADREN RECEPT BLOCK, BETA ADREN BLOCK, ADREN BETA ANTAG, ADRENERGIC ANTAGONISTS BETA, ADRENERGIC RECEPTOR BLOCKADERS BETA, BETA ADREN BLOCK AGENTS, beta adrenergic blocking agents (medication), adrenergic beta receptor blockaders, beta adrenergic blocking agents, Adrenergic beta-Antagonists, Beta-Blockers, Beta Blocker, beta-adrenergic receptor blockaders, beta-adrenergic blocking agents, beta adrenergic blockers, beta blocker, beta blockers, beta-adrenergic blocking agent, beta-blocking agent, beta adrenergic antagonist, beta adrenergic blocker, beta-blocker, beta-adrenergic blockers, BETA BLOCKING AGENTS, Beta-adrenoceptor blocking drug (substance), Beta blockers, Adrenergic beta blockers, Beta-adrenoceptor blocking drug, Beta-blocker, beta-Adrenergic blocking agent, beta-Blocking agent (product), beta-Blocking agent (substance), beta-Blocking agent, Beta-adrenoceptor blocking agent, beta-Adrenergic blocking agent, NOS, beta-Blocking agent, NOS, Beta Blockers, Beta-Adrenergic Antagonist, Beta-Adrenergic Blocking Agent, Beta-adrenergic Blocking Agents |
French | Bêta-bloquants adrénergiques, Antagonistes des adrénorécepteurs bêta, Agents bloquants bêta-adrénergiques, Bêta-adrénolytiques, Bêta-bloquants, Adrénolytiques bêta, Antagonistes bêta-adrénergiques, Antagonistes des récepteurs adrénergiques bêta, Bêta-bloqueurs |
Swedish | Adrenerga betablockerare |
Spanish | bloqueantes beta, Antagonistas Adrenérgicos beta, Agentes Bloqueadores Adrenérgicos beta, Bloqueadores Adrenérgicos beta, Bloqueadores de los Receptores Adrenérgicos beta, Bloqueadores beta Adrenérgicos, beta-Antagonistas Adrenérgicos, Agentes Bloqueadores beta-Adrenérgicos, Bloqueadores de los Receptores beta Adrenérgicos, Bloqueadores de los Receptores beta-Adrenérgicos, agente betabloqueante (producto), agente betabloqueante (sustancia), agente betabloqueante, antiadrenérgicos beta, betabloqueantes, bloqueantes beta (producto), bloqueantes beta (sustancia) |
Czech | beta-adrenergní blokátory, betablokátory, receptory adrenergní beta - blokátory, beta-blokátory, antagonisté beta-adrenergních receptorů, blokátory adrenergních beta-receptorů, blokátory betaadrenergních receptorů |
Finnish | Beetasalpaajat |
Italian | Bloccanti dei recettori adrenergici, Agenti bloccanti beta-adrenergici, Bloccanti beta-adrenergici, Beta-antagonisti adrenergici |
Russian | ADRENERGICHESKIE BETA-ANTAGONISTY, ADRENERGICHESKIKH BETA-RETSEPTOROV BLOKATORY, BETA-ADRENERGICHESKIKH RETSEPTOROV BLOKATORY, BETA-ADRENOLITICHESKIE SREDSTVA, BETA-ADRENOLITIKI, BETA-BLOKATORY ADRENERGICHESKIE, АДРЕНЕРГИЧЕСКИЕ БЕТА-АНТАГОНИСТЫ, АДРЕНЕРГИЧЕСКИХ БЕТА-РЕЦЕПТОРОВ БЛОКАТОРЫ, БЕТА-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ БЛОКАТОРЫ, БЕТА-АДРЕНОЛИТИКИ, БЕТА-АДРЕНОЛИТИЧЕСКИЕ СРЕДСТВА, БЕТА-БЛОКАТОРЫ АДРЕНЕРГИЧЕСКИЕ |
German | ADRENERGE REZEPTORENBLOCKER BETA, ADRENERGE ANTAGONISTEN BETA, Adrenerge Beta-Antagonisten, Adrenerge Beta-Rezeptorenblocker, Beta-Blocker, adrenerge, Beta-adrenerge Blocker, Beta-adrenerge Rezeptorenblocker |
Croatian | ADRENERGIČKI BETA-ANTAGONISTI |
Polish | Środki blokujące receptory adrenergiczne beta, Leki blokujące receptory beta-adrenergiczne, Beta-adrenolityki, Blokery beta, Antagoniści adrenergiczni beta |
Japanese | β-アドレナリン作動性受容体遮断薬, β-遮断剤, β-ブロッカー, β-受容体遮断薬, β-遮断薬, アドレナリンベータきっ抗剤, アドレナリン作用性ベータ受容体遮断剤, アドレナリン作用性ベータ受容体遮断薬, アドレナリン作用性ベータ拮抗薬, アドレナリン作用性ベータ遮断薬, ベータアドレナリン作用性受容体遮断薬, ベータアドレナリン作用性遮断薬, β-アドレナリン受容体遮断薬, β-アドレナリン遮断薬, β受容体遮断薬, β遮断薬, アドレナリンベータアンタゴニスト, アドレナリンベータブロッカー, アドレナリン作用性ベータ受容器遮断薬, ベータ遮断剤 |
Portuguese | Antagonistas Adrenérgicos beta, Bloqueadores dos Receptores Adrenérgicos beta, Agentes Bloqueadores Adrenérgicos beta, Bloqueadores Adrenérgicos beta, Bloqueadores beta Adrenérgicos, Agentes Bloqueadores beta-Adrenérgicos, Bloqueadores dos Receptores beta-Adrenérgicos, beta-Antagonistas Adrenérgicos, Bloqueadores dos Receptores beta Adrenérgicos |